Decentralized Structure Introduced By Degussa
From now on, German chemical and pharmaceutical company Degussa will operate 11 decentralized business units which will be organized into three segments: chemical products; health and nutrition; and precious metals and banking, the firm announced recently.
Efforts to streamline the firm started back in 1992 under the banner of Degussa 2000. The current reorganization is intended to focus the group even more, and is being tackled by Uwe-Ernst Bufe, president and chief executive of the group since March this year.
The health and nutrition segment is built up on three strong pillars of growth, said Degussa, comprising Asta Medica, and the dental and animal feed additives divisions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze